Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering

Abstract:
WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012. A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000. Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer. WestPark Capital, Inc. acted as placement agent for the offering.

WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering

Los Angeles, CA | Posted on January 20th, 2012

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by Confidential Private Placement Memorandum. Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

####

About WestPark Capital, Inc.
WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them. WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at . Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a new generation of diagnostic and therapeutic drugs based on a new family of nano-biopolymers. Arrogene was founded in 2007 to commercialize a new cancer targeting technology and a proprietary molecular delivery platform that interferes with cancer targets to inhibit and finally eradicate tumor progression. Additional information about Arrogene is available at www.arrogene.com.

For more information, please click here

Contacts:
WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers find the 'key' to quantum network solution May 25th, 2015

One step closer to a single-molecule device: Columbia Engineering researchers first to create a single-molecule diode -- the ultimate in miniaturization for electronic devices -- with potential for real-world applications May 25th, 2015

DNA Double Helix Does Double Duty in Assembling Arrays of Nanoparticles: Synthetic pieces of biological molecule form framework and glue for making nanoparticle clusters and arrays May 25th, 2015

Engineering Phase Changes in Nanoparticle Arrays: Scientists alter attractive and repulsive forces between DNA-linked particles to make dynamic, phase-shifting forms of nanomaterials May 25th, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

BESSTECH Announces $250K Investment from Eastern New York Angels : Funding will accelerate commercialization of BESSTECH’s innovative lithium-ion battery electrode technology and enable hiring of key personnel May 13th, 2015

Harris & Harris Group Portfolio Company OpGen Raises $17.1 Million in Initial Public Offering May 6th, 2015

Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Nanomedicine

DNA Double Helix Does Double Duty in Assembling Arrays of Nanoparticles: Synthetic pieces of biological molecule form framework and glue for making nanoparticle clusters and arrays May 25th, 2015

Nanostructures Increase Corrosion Resistance in Metallic Body Implants May 24th, 2015

Iranian Scientists Use Magnetic Field to Transfer Anticancer Drug to Tumor Tissue May 24th, 2015

New Antibacterial Wound Dressing in Iran Can Display Replacement Time May 22nd, 2015

Announcements

Researchers find the 'key' to quantum network solution May 25th, 2015

One step closer to a single-molecule device: Columbia Engineering researchers first to create a single-molecule diode -- the ultimate in miniaturization for electronic devices -- with potential for real-world applications May 25th, 2015

DNA Double Helix Does Double Duty in Assembling Arrays of Nanoparticles: Synthetic pieces of biological molecule form framework and glue for making nanoparticle clusters and arrays May 25th, 2015

Engineering Phase Changes in Nanoparticle Arrays: Scientists alter attractive and repulsive forces between DNA-linked particles to make dynamic, phase-shifting forms of nanomaterials May 25th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project